Rectify is developing Positive Functional Modulators (PFMs), disease-modifying precision therapeutics that restore ABC transporter function for patients with serious genetic diseases.

ABC transporters are a 48-member family of membrane-bound proteins with etiologic loss-of-function mutations in multiple organ systems and therapeutic areas including the lungs, liver, gastrointestinal tract, eye, and central nervous system.

Headquarters 300 Technology Square, 8th Floor, Cambridge, MA 02139
Pipeline Preclinical
Twitter @RectifyPharma
LinkedIn RectifyPharma